The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

Abstract Background Lung cancer is the most common cause of cancer-related mortality worldwide despite diagnostic improvements and the development of targeted therapies, notably including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The phosphoinositide 3-kinase (PI3K)/...

Full description

Bibliographic Details
Main Authors: Yi-Ying Wu, Hung-Chang Wu, Jia-En Wu, Kuo-Yen Huang, Shuenn-Chen Yang, Si-Xuan Chen, Chao-Jung Tsao, Keng-Fu Hsu, Yuh-Ling Chen, Tse-Ming Hong
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Lung cancer
BEZ235
PI3K/mTOR
EGFR
Combined therapy
Online Access:http://link.springer.com/article/10.1186/s13046-019-1282-0

Internet

http://link.springer.com/article/10.1186/s13046-019-1282-0

Similar Items